Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Volatility watch: Some of the volatility names to watch include Colony Capital (NYSE: CLNY ) , American Eagle Outfitters (NYSE: AEO ) and Brookfield Property Partners (NASDAQ: BPY ) with short interest positions on the rise. Virgin Galactic (NYSE: SPCE ) and National Beverage (NAS...
Galapagos (NASDAQ: GLPG ) has collaborated with privately-held Scipher Medicine, to advance drug targets identified by latter for the treatment of inflammatory bowel disease (IBD). More news on: Galapagos NV, Galapagos NV, Galapagos N.V. ADR, Healthcare stocks news, Read more ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q2 2020 Earnings Call Aug 7, 2020 , 8:00 a.m. ET Operator Continue reading
Galapagos NV (GLPG) Q2 2020 Results Earnings Conference Call August 07, 2020, 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Piet Wigerinck - Chief Scientific Officer Walid Abi-Saab - Chief Medical Officer ...
Galapagos (NASDAQ: GLPG ) : 1H GAAP EPS of -€2.55. More news on: Galapagos NV, Earnings news and commentary, Healthcare stocks news, Read more ...
Gilead ( GILD ) - first, the bear case GILD reported Q2 results Thursday. The stock, which had begun underperforming the sector ( IBB ), dropped further, and on a weak day for biotech Friday closed down 3.9% at $69.53. After having led the sector up this year, it is now lagging IBB's to...
Biotech investors can get ready for a busy month full of stock-moving binary events. All of these companies are waiting for the FDA to make some very important approval decisions. Here's what you should know about three of the most important approval decisions expected over the next several wee...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Gilead Sciences (NASDAQ: GILD ) and collaboration partner Galapagos NV's (NASDAQ: GLPG ) JAK inhibitor filgotinib, branded as Jyseleca, for adults with moderate-to-severe rheumatoi...
-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...